Instruction for use: Madopar

Dosage form: capsules

Active substance: Levodopa + Benserazide*

ATX

N04BA Dopa and its derivatives

Pharmacological groups:

Dopaminomimetics in combinations

Antiparkinsonics in combinations

The nosological classification (ICD-10)

G20 Parkinson's disease: A trembling paralysis; Idiopathic Parkinsonism; Parkinson's disease; Symptomatic Parkinsonism

G21 Secondary Parkinsonism: Medicinal Parkinsonism; Parkinsonism; Parkinsonism symptomatic; Disorders of extrapyramidal system; Parkinson's Syndrome

Composition and release form

1 capsule contains levodopa 100 mg and benserazide (as chloride) 25 mg; In a glass jar 100 pcs., In a box of 1 can.

Pharmachologic effect

The pharmacological action is antiparkinsonian.

Increases the content of dopamine in the central nervous system (levodopa) and reduces hypokinesia, rigidity, tremor; Inhibits peripheral decarboxylase (benserazide), reducing the accumulation of dopamine outside the central nervous system.

Indications of the Madopar

Parkinson's disease, symptomatic parkinsonism (with the exception of medication).

Contraindications

Diseases of the endocrine system, kidneys, liver, heart, psychosis, pregnancy, age (under 25 years).

Side effects

Insomnia, a sense of anxiety, depression, choreal and lethargic movements; In rare cases - leukopenia, thrombocytopenia.

Dosing and Administration

Inside. The dose is selected individually.

Precautionary measures

At the beginning of treatment, one should not abruptly discontinue the use of other antiparkinsonian drugs. It is not recommended to combine with MAO inhibitors. With prolonged use, it is necessary to monitor the blood picture, kidney and liver function

Storage conditions of the drug Madopar

Keep out of the reach of children.

Shelf life of the drug Madopar

3 years.

Do not use after the expiry date printed on the package.